Purpose: We sought to determine if specific genetic single nucleotide polymorphisms (SNPs) influence vascular endothelial growth factor inhibition response to ranibizumab in neovascular age-related macular degeneration (AMD).
Introduction
Age-related macular degeneration (AMD) is a chronic, progressive disease of the central retina. Macular changes related to ageing are typically classified into one of four categories: normal agerelated changes, early AMD, intermediate AMD or late AMD (Ferris et al. 2013) . Most visual loss happens in late AMD due to neovascular (i.e., wet AMD) or geographic atrophy (dry AMD; Lim et al. 2012) . Age-related macular degeneration (AMD) is the leading cause of low vision and legal blindness in adults in developed countries, and its prevalence is expected to increase in the next few decades. While no good treatments have yet been found for dry AMD, effective treatmentsprimarily the use of antivascular endothelial growth factor (anti-VEGF) inhibitors-are available for wet AMD (Rasmussen et al. 2017) . However, these require repeated and expensive intravitreal injections that cannot be delayed (Real & Luna 2016) and frequent ophthalmological examinations, thus making treatment costly and time consuming, so AMD is likely to become an increasingly challenging problem for healthcare systems worldwide (Rein et al. 2006; Kume et al. 2016; Wu et al. 2016) .
Age-related macular degeneration (AMD) is a multifactorial disease influenced by age, genetic and environmental factors, such as smoking, obesity, hypertension and cardiovascular disease (Sobrin & Seddon 2014) . Numerous reports have found that certain genetic variants are strongly associated with a high risk of developing AMD, concluding that AMD heritability is as high as 71% (Edwards et al. 2005; Haines et al. 2005; Klein et al. 2005; Seddon et al. 2005; Holliday et al. 2013 ; The AMD Gene Consortion 2013; Dietzel et al. 2014; Lechanteur et al. 2015) . It is a polygenic disease and multiple common genetic variants contribute to its development (Chen et al. 2010; Arakawa et al. 2011; Almeida et al. 2013; Holliday et al. 2013; Fritsche et al. 2014; Black & Clark 2016 ). Genetic loci from several different pathways may be involved in the development and progression of AMD, including genes associated with lipid and extracellular matrix dysregulation, DNA repair, immune response and inflammation. One of the most important pathways associated with AMD are the complement cascade genes (Klein et al. 2005; Patel et al. 2008; Recalde et al. 2008; Gorin 2012; Mart ınez-Barricarte et al. 2012; Sobrin & Seddon 2014; Grassmann et al. 2015; Hall et al. 2015) . Many genome-wide association studies have been performed in this field in recent years, and as a result the number of SNPs associated with the risk of developing AMD has increased (Neale et al. 2010; Arakawa et al. 2011; Fritsche et al. 2016) .
Age-related macular degeneration (AMD) treatments have improved greatly in recent decades. Although photodynamic therapy was proven effective in reducing the rate of visual loss nearly 20 years ago (American Academy of Ophthalmology 2000), the development of anti-VEGF therapy revolutionized the treatment of AMD due to the encouraging outcomes in preventing visual loss and increasing visual acuity (VA) (The Eyetech Study Group 2003) . Many patients are now able to maintain their vision, with a third of patients gaining 15 letters or more (Rosenfeld et al. 2006) , and with less visits thanks to new treatment regimens (Kvannli & Krohn 2017) . However, despite the good results for most patients, there is a subgroup of patients that not only fail to recover their vision, but also continue losing VA despite treatment (Kanoff & Miller 2013) .
At present, it is not possible to predict which patients will respond to treatment. If we could predict the likely response to ranibizumab before treatment, it would be possible to alter the treatment approach in patients expected to be poor or non-responders. In such cases, we could monitor the patients more closely, use more active treatment regimens or administer (in the future) new targeted drugs. Several studies have attempted to determine if genetic factors predispose patients with late AMD to a poor response to anti-VEGF therapy (McKibbin et al. 2012; Abedi et al. 2013a,b; Kanoff & Miller 2013; Park et al. 2014a ). However, the results to date have been ambiguous. Indeed, rather than clarifying this issue, the available research appears to have generated more confusion, perhaps due to methodological and demographic differences among the various studies. These studies range from clinical trials with highly restrictive inclusion and exclusion criteria that do not reflect the usual conditions of daily clinical practice to clinical studies with small sample sizes that do not evaluate genes related to anti-VEGF response.
Given this context, particularly the scant data in real-life clinical samples, we carried out the current retrospective study to examine nine SNPs from six different genes previously associated with AMD, including complement and angiogenesis genes as well as genes related to anti-VEGF response. The main aim was to determine whether the presence of these SNPs was associated with anatomical and functional response to ranibizumab treatment in a cohort of Spanish patients treated in real-life clinical practice.
Materials and Methods

Study subjects
This study included 403 eyes from 403 consecutive Caucasian patients (230 women and 173 men) diagnosed with unilateral exudative AMD. It is a retrospective, observational, multicenter, cohort study conducted between January 2015 and May 2016. All patients were treated with intravitreal ranibizumab injections according to the Spanish Vitreo Retinal Society (SERV) guidelines (three-injection loading phase followed by a pro re nata [PRN] treatment regimen). Our study population was retrospectively recruited from six Spanish tertiary care Hospitals (all members of the Spanish Multicenter Group on AMD and the "Red Tem atica de Investigaci on Cooperativa en Salud," RD07/0062).
General inclusion criteria were as follows: diagnosis of AMD with active subfoveal or juxtafoveolar choroidal neovascularization (CNV) confirmed by fluorescence angiography (FA) and optical coherence tomography (OCT) and treated with ranibizumab. Exclusion criteria were as follows: previous treatment with photodynamic therapy or another antiVEGF drug; previous vitrectomy in the study eye; tractional maculopathy and/or epiretinal membrane on the OCT; corneal or lens opacities; lack of integrity of the posterior lens capsule; presence of other retinal diseases associated with CNV; and presence of central serous chorioretinopathy. All patients completed a demographic questionnaire and gave permission for inclusion in a database (Data protection consent) and written informed consent in accordance with the Declaration of Helsinki and with the institutional ethics review boards of the Cl ınica Universidad de Navarra.
Clinical data collection
Patients underwent a complete ophthalmic examination at every consultation, including determination of best corrected visual acuity (BCVA) measured with ETDRS charts at 4 m distance, slit-lamp examination, fundus examination and spectral domain optical coherence tomography (SD-OCT). Central foveal thickness (CFT) and the presence of persistent or recurrent intraretinal or subretinal fluid were assessed by SD-OCT. At the initial consultation, a FA was performed to determine the type of lesion and the size of the neovascular complex. Angiographic subtypes were defined as follows: predominantly classic, minimally classic or occult. Re-treatment criteria in the monthly consultations after the first three injections were as follows: persistent or recurrent fluid on SD-OCT, loss of >5 letters, new macular haemorrhage or CFT increase >100 lm.
Response evaluation criteria
Patients were classified into two groups-good or poor responders (GR or PR)-for a binomial calculation, according to their response to ranibizumab treatment on the study criteria. Good responders were defined as follows: patients with a gain of ≥5 letters of VA measured by ETDRS (functional criteria); reduction of CFT measured by OCT (anatomical criteria); and absence of fluid on OCT (fluid criteria). Poor responders (PR): patients with a gain of less than 5 letters, without reduction in CFT and persistence of fluid on OCT.
Central foveal thickness was measured at the foveola (between retinal inner surface and retinal pigment epithelium) by OCT at baseline, after the loading phase and after 12 months of treatment. Patients with stable CFT or with an increase in CFT were classified as non responders. Patients with a reduction in CFT were classified as good responders.
Non-genetic risk factors (gender, age, age of diagnostic, tobacco and hypertension) were also assessed. Smoking was defined as active and exsmokers of <20 years.
Genotyping
We reviewed the published literature on genetic associations in AMD and VEGF response to identify the SNPs that showed the most significant associations with AMD (CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF) and genes that play an important role in the angiogenesis pathway and were good candidates to explain difference in treatment response. These SNPs were selected for this study.
Genomic DNA was extracted from oral swabs using QIAcube (QIAGEN, Valencia, CA). DNA samples were genotyped using nine SNPs from six different genes (CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF) to assess their influence on response to ranibizumab. Genotyping was performed by multiplex PCR and minisequencing. All SNPs analysed in this report were in Hardly-Weingberg equilibrium. The characteristics of the candidate polymorphisms are listed in Table 1 .
Statistical analysis
The continuous variables (current age and age at diagnosis) were divided into two groups, and the median value for these variables was used as a cut-off point and codified as categorical variables. A multivariable logistic regression model was used to study the association between the nine SNPs and patient response (good or poor responder) to ranibizumab. The model was adjusted to account for environmental variables, which were included as covariates in the regression model.
A univariate logistic regression, adjusted for all covariates, was used to estimate the odds ratios (OR) and 95% confidence intervals (95% CI) using SNPStats software (Sole et al. 2006) . Analyses were performed for each genetic variant independently of other variants using codominant, dominant, recessive and/or overdominant genetic models based on Akaike information criteria (AIC), which chooses the inheritance model that best fits the data. Correction for multiple testing was performed using the Bonferroni method. For all analyses, p < 0.05 was considered statistically significant. A multivariate logistic regression was also performed.
Results
The study included 403 patients (230 women and 173 men). The demographic and clinical characteristics of the study population are summarized in Table 2 . Patients were classified into two groups according to their response (good or poor response) to ranibizumab on the following variables: VA (functional criteria), macular thickness measured by OCT (anatomical criteria) and presence or absence of fluid measured by OCT (fluid criteria). There was no statistical significant difference between groups in the number of injections received in 12 months (p > 0.05).
Our data show that hypertension was a clear risk factor for a poor anatomical response. A comparison of the whole group to the good responder group subset after the loading phase (p = 0.048; OR, 0.7; 95% CI, 0.5-0.9) and after 12 months of treatment (p = 0.003; OR, 0.6; 95% CI 0.4-0.8) revealed a significant statistical difference. This difference was even greater when comparing the presence of hypertension in good responders versus poor responders after the loading phase (p = 0.0004; OR 3.7; 95% CI, 2.4-5.8) and after 12 months of treatment (p = 0.00001; OR 2.3; 95% CI, 1.5-3.4).
Smoking was found to be a risk factor for not achieving a dry macula at 12 months of treatment (GR versus PR: p = 0.036; OR, 1.7; 95% CI, 1.1-2.7). Females were more likely to present a poor anatomical response at 12 months of treatment (GR versus PR: p = 0.036; OR, 1.7; 95% CI, 1.1-2.7). Table 3 shows the pharmacogenetic results of the univariate analysis after the loading phase. On VA measures, the A allele of rs12603486 (SERPINF1) was associated with a risk of poor response (OR 2; 95% CI, 1.4-3; p = 2 9 10 À4 ; corrected p, 0.0018). In the recessive model, the GG/GA genotypes versus AA genotype were associated with a poor functional response (OR, 4.4; 95% CI, 1.0-10.0; p = 5 9 10
À4
; corrected p, 0.0045). In the overdominant model, patients with the C/T versus the C/C-T/T genotype at rs12614 (CFB) were more likely to achieve better VA results (OR 0.5; 95% CI, 0.2-0.9; p = 0.03; corrected p, 0.27), although this result was no longer significant after the Bonferroni correction.
In terms of anatomical outcomes after the loading phase, the G allele of rs1136286 (SERPINF1) was associated with less reduction in CFT (OR 1.5; 95% CI, 1.1-2.0; p = 0.02; corrected p, 0.18), but without reaching significance after the Bonferroni correction. The T/C-C/C versus T/T genotypes of rs1061170 (CFH) and rs7993418 (VEGFR1) were both associated with a better anatomical response in the dominant model (p = 0.04 and p = 0.02, respectively). In the recessive model, AA versus GG/GA of rs800292 (CFH) was associated with a poor anatomical response (p 0.0048; corrected p, 0.043). Table 4 summarize the pharmacogenetic results of the univariate analysis after 12 months of treatment. The C allele of rs1136287 (SERPINF1) was associated with less reduction in CFT (OR 1.7; 95% CI, 1.1-2.8; p = 0.02; corrected p, 0.18). On the dominant model, patients with C/T-C/C genotypes were 2.1 times (95% CI, 1.1-4.2; p = 0.03; corrected p, 0.27) more likely to have a poor anatomical response than patients carrying the T/T genotype. On the overdominant model, the C/T genotype of rs7993418 (VEGFR1) was associated with a good anatomical response (OR 0.5, 95% CI, 0.2-0.9; p = 0.03; corrected p, 0.27), but this finding was not statistically significant after Bonferroni correction.
In terms of the presence or absence of intraretinal fluid in the OCT at 12 months, the A allele of rs800292 (CFH) was more prevalent in patients that had not achieved a dry macula (OR 1.7; 95% CI, 1.1-2.7; p = 0.02; corrected p, 0.19). G/A and A/A were the most prevalent genotypes in this group of persistent intraretinal fluid according to the dominant model (OR 1.8; 95% CI, 1.1-3.1; p = 0.028; corrected p, 0.25).
None of the other SNPs evaluated in this study showed any statistically significant association with ranibizumab response. Table 5 summarize the results of the multivariate logistic regression analysis, We also analysed the association between these SNPs and continuous variables such as CFT and VA. Interestingly, patients who had a protective genotype (AA) for neovascular AMD of rs800292 (CFH) had better pretreatment VA than patients with other genotypes (AG/GG), but their response to ranibizumab was significantly inferior in terms of VA after the first injection and after the loading phase. They improve more gradually than patients with AG/GG genotypes, who have an intense response during the firsts 3 months of treatment, with a final stabilization. Nevertheless, their final VA at 12 months was worse than patients with AA genotype.
Discussion
The number of patients evaluated in the present pharmacogenetic study is among the highest reported to date. We hypothesized that the variable response to anti-VEGF treatment observed in clinical practice could be explained by genotype. We analysed not only AMD risk genes, but also genes associated with VEGF regulation such as SER-PINF1, VEGFA and VEGFR. We found-for the first time-that the presence of SERPINF1 is associated with poor outcomes in terms of VA and decreased CFT. CFH, VEGFA and VEGFR1 genes, are associated with treatment response. Finally, our data confirm that certain environmental factors, particularly hypertension, have an important influence on treatment outcomes.
It is well-known that genetic factors play an important role in the pathogenesis of AMD. In recent years, many Most studies of AMD are clinical trials, with all the benefits and drawbacks that entails: strict inclusion and exclusion criteria, high homogeneity but less representative of general population, and with a possible genetic bias. By contrast, this was a retrospective study of daily clinical practice that included a large sample of AMD patients that is highly representative of the neovascular AMD population in Spain. As a result, the external validity of our study is high.
After a first pilot study conducted with a small sample size and analysing only three SNPs (ARMS2 rs10490923, CFH rs1410996 and HTRA1 rs11200638), where no association with ranibizumab response was found (Cruz-Gonzalez et al. 2016), we decided to conduct a study increasing sample size and studying genes not only related with AMD risk, but also with VEGF and their receptor. We grouped patients into one of two groups-good or poor respondersaccording to their response (VA and anatomical) to ranibizumab treatment at two time points: after the loading dose and after 12 months of follow-up. Because VA can be a subjective measure and may not correlate well with changes in macular anatomy detected on OCT, we evaluated treatment response using both VA measures and tomographic results. For this reason, we used CFT and the presence or absence of intraretinal and subretinal fluid as objective measures. SERPINF1 (or PEDF) is a protein secreted by human retina pigment epithelial cell. It is a potent antiangiogenic agent that inhibits the migration of endothelial cells. SERPINF1 also contributes to the regulation of blood vessel growth in the eye by creating a permissive environment for angiogenesis * Uncorrected p-value: value from logistic regression model; p-value significance <0.05; ** p-value corrected for multiple testing using Bonferroni method.
when oxygen is limited and an inhibitory environment when oxygen concentration is normal or high (Dawson et al. 1999) . Given the important role of SERPINF1 in the angiogenesis pathway, it is not surprising that this protein could be an important biomarker in AMD pharmacogenetics. Several authors have studied the association between SERPINF1 (rs1136287) and visual outcomes after intravitreal bevacizumab or ranibizumab (Imai et al. 2010; Park et al. 2014a,b) , without finding any significant association between this SNP and post-treatment functional and/or anatomical outcomes. However, ours is the first pharmacogenetic study of AMD to include rs12603486. Ours is the first study to find a statistically significant association between both SERPINF1 SNPs (rs12603486 and rs1136287) and visual and tomographic outcomes after ranibizumab treatment.
CFH is a regulator of the basal activation of the alternative pathway of the complement cascade, and thus, it has an anti-inflammatory role (Thakkinstian et al. 2006 ). The inflammatory pathogenesis theory is supported by the existence of multiple complement-related AMD risk alleles (Maller et al. 2006; Francis et al. 2009; Sobrin & Seddon 2014 ).The rs1061170 of CFH has been associated with all forms of AMD in various populations worldwide (Edwards et al. 2005; Haines et al. 2005; Leveziel et al. 2011) . We found that the CC genotype of rs1061170 in CFH (the principal risk genotype) was significantly associated (before Bonferroni correction) with a better anatomical response after the ranibizumab loading phase. Our results suggest that AMD patients who carry the risk allele will respond initially better to ranibizumab in terms of anatomical outcomes than patients without this allele. This finding seems to contradict the results of other studies in which outcomes (VA, number of injections) were worse in patients carrying the risk genotype of CFH rs1061170 (Brantley et al. 2007; Lee et al. 2009; Imai et al. 2010; Francis 2011; Kloeckener-Gruissem et al. 2011; Nischler et al. 2011; Smailhodzic et al. 2012; Shah et al. 2016) . Nevertheless, our findings are consistent with those reported by McKibbin et al. (2012) . Those authors hypothesized that patients carrying AMD risk alleles would benefit most from anti-VEGF therapy. We found that risk genotype is associated with better anatomical response but not better functional response. However, after Bonferroni correction, this result was not statistically significant and was not confirmed at 12 months of follow-up. Figure 1A -D show the differences in VA and CFT between genotypes of rs800292 in CFH. Patients with the AA genotype (protective genotype) presented significantly better VA and less CFT before treatment and the loading phase, but also had persistent intraretinal fluid after 12 months of treatment. Patients with this genotype appear to show a better initial profile, but they have a sustained VA improving after treatment, comparing with the intense response of the patients with a high-risk profile (GA/GG genotypes). In these patients, we suspect that the protective genotype of rs800292 could cause AMD patients to develop a less aggressive form of wet AMD, and thus, the anti-VEGF response (especially 
Retrospective study/ 101 USA 10 VEGFA rs699947(CC), VEGFA rs833061(CT) and VEGFA rs1570360(GG): more likely to be non responders LOC387715 rs10490924(TT): more likely to be non responders after the loading phase) may be less effective. In the case of rs1061170 (CFH), the effect could be the opposite.
Another important anti-VEGFrelated gene is VEGFR1. This gene encodes for a tyrosine kinase receptor (TKR) and transmits signalling from several members of the VEGF family.
The VEGFR1 signalling route plays an important role in angiogenesis as well, particularly in pathological conditions such as AMD (Huang et al. 2011) . We found that VEGFR1-E28 rs7993418 was associated with a good anatomical result after the loading phase and after 12 months of treatment. The association between this gene and anti-VEGF treatment response was previously studied by Hermann et al. (2014) without finding any relation.
In addition to certain genetic associations, environmental factors such as hypertension, age, gender and smoking habit have also been associated with ranibizumab response (Chakravarthy et al. 2010 ). According to our results, not only hypertension is the environmental factor most strongly associated with AMD development but also it is associated with a poor ranibizumab response, a finding that has not been previously described. All these environmental factors could explain pharmacogenetic discrepancies between cohorts of patients from different countries.
Among the most important pharmacogenetics studies of AMD (Table 6) , only the investigation conducted by Park et al. (2014b) , Kitchens et al. (2013) , Matsumiya et al. (2014) and Lotery et al. (2013) found statistically significant results in terms of anatomical response to anti-VEGF therapy. Park and colleagues reported that ARMS2 (rs10490924) and HTRA1 (rs11200638) were associated with a greater reduction in CFT. Kitchens et al. found that LOC387715 (rs10490924) was associated with a poor anatomical result. Matsumiya et al. observed poor resolution of the intraretinal fluid in patients with the combination of the variants CFH I62V + CFH Y402H. In the IVAN study, Lotery et al. found no statistically significant association between the nearly 500 SNPs assessed and the anatomic response, although the one with the strongest result was rs9679290 in EPAS. Our findings show that other genetic variants: SERPINF1 (rs1136287), VEGFR1 (rs7993418) and CFH (rs800292), are associated with good anatomical results.
The primary genes associated with VA outcomes are VEGFA and CFH, as shown in Table 5 (Imai et al. 2010; Kloeckener-Gruissem et al. 2011; Smailhodzic et al. 2012; Abedi et al. 2013a; Hagstrom et al. 2013; Kitchens et al. 2013; Park et al. 2014a,b) . In our study, the strongest associations in functional response were observed with SERPINF1, CFB, CFH and VEGFR1.
Study strengths and limitations
The sample size (404 eyes) of our study is among the largest of all pharmacogenetic studies of AMD conducted to date. However, this sample was still insufficient to achieve strong statistical results on some outcome measures. A second limitation is that we evaluated only five SNPs (VEGFA, VEGFA-P, VEGFR and two SNPs of SERPINF1) related to ranibizumab response, yet our results suggest that these genes play an important role in differences in treatment response, and thus, it would have been helpful to study more SNPs related to these genes. Nevertheless, our study is a real-life study, and response to ranibizumab was evaluated not only measuring VA, but also with objective measures as CFT and presence of fluid in OCT.
Conclusions
In conclusion, this study investigated the pharmacogenetic association between nine AMD-relevant SNPs and anatomical and functional response to ranibizumab in a real-life cohort of Spanish patients. The most important novel finding of this study is that SERPINF1 is associated with poor VA outcomes and a reduction of CFT after treatment. This is the first time that SERPINF1 has been implicated in ranibizumab response in AMD patients. We also found that VEGFR1 is associated with treatment response, which is a novel finding too. Our VEGFA confirm previous studies' results. CFH protective genotype is associated with a poor ranibizumab response. The present study also confirms the importance of environmental factors, particularly hypertension, in treatment outcomes. Based on our results, SERPINF1 and hypertension may both be good candidates for use as biomarkers of treatment response in AMD patients. As our results demonstrate, genetic variation clearly plays an important role in response to ranibizumab in AMD patients, although more real-life pharmacogenetics studies in other cohorts of patients are needed to confirm these findings.
